Supriya Lifescience (SUPRIYA) Fundamentals 2026 — P/E 32.3x, Revenue Analysis | SniperIQ
Supriya Lifescience (SUPRIYA) is a India-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₹6,766 Crore, trading at ₹840.45 on the BSE. This SniperIQ fundamentals page covers Supriya Lifescience's valuation (P/E 32.3x, P/B 5.6x), profitability (net margin 25.3%), revenue (₹828 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Supriya Lifescience's market cap?
Supriya Lifescience (SUPRIYA) has a market capitalization of approximately ₹6,766 Crore, trading at ₹840.45 on the BSE. Market cap moves with the live share price.
What is Supriya Lifescience's P/E ratio?
Supriya Lifescience's trailing twelve-month P/E ratio is 32.3x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Supriya Lifescience?
Supriya Lifescience runs a net profit margin of 25.3%, a gross margin of 65.3%, and an operating margin of 32.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Supriya Lifescience generate?
Supriya Lifescience reported revenue of ₹828 Crore for fiscal year 2026, with net income of ₹209 Crore and earnings per share (EPS) of 25.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Supriya Lifescience pay a dividend?
Supriya Lifescience offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Supriya Lifescience financially healthy?
Supriya Lifescience carries a debt-to-equity ratio of 0.00x and a current ratio of 4.40x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Supriya Lifescience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Supriya Lifescience (SUPRIYA) the key facts are: market cap ₹6,766 Crore, P/E 32.3x, revenue ₹828 Crore, 52-week range 545.65-1085.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Supriya Lifescience's full fundamentals live
Get Supriya Lifescience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.